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Branch retinal vein occlusion (BRVO) is one of the most 
common retinal vascular diseases [1]. Loss of visual function 
in BRVO is often caused by macular edema. Bevacizumab 
is an anti-vascular endothelial growth factor (VEGF) agent 
frequently used for the treatment of macular edema following 
BRVO. Bevacizumab is a full-length monoclonal immuno-
globulin G (IgG) antibody that binds and neutralizes all 
isoforms of VEGF-A [2]. Although the efficacy of bevaci-
zumab is well documented, there is only limited knowledge 
about the large-scale retinal protein changes caused by beva-
cizumab in BRVO [3].
Inhibition of VEGF with bevacizumab is likely to change 
the retinal content of a multitude of proteins. Proteins that 
mediate the beneficial effect of bevacizumab may serve as 
potential therapeutic targets and may be useful in improving 
existing anti-VEGF regimens. In the present study, an 
intravitreal bevacizumab intervention was tested in an 
experimental porcine model of BRVO followed by proteomics 
analysis.
METHODS
Animal preparation: The study was approved by the 
Danish Animal Experiments Inspectorate, permission no. 
2016–0201-00971, and the experiments were conducted in 
accordance with the guidelines published by the Institute for 
Laboratory Animal Research. The study was conducted in 
adherence to the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. The animals were housed 
under a 12 h:12 h light-dark cycle. Anesthesia was performed 
with an intramuscular injection of Zoletil mixture consisting 
of ketamine 6.25 mg/ml and tiletamine 6.25 mg/ml, zolaz-
epam 6.25 mg/ml, butorphanol 1.25 mg/ml, and xylazine 
6.5 mg/ml. The dosage of the Zoletil mixture was 1 ml/10 
kg. Dilation of the pupils was performed as described in a 
previous work [4].
Branch retinal vein occlusion and bevacizumab interven-
tion: An experimental overview is provided in Figure 1. 
Six Danish Landrace pigs were used for the experiments. 
BRVO was induced in both eyes of the animals by occluding 
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Purpose: To identify retinal protein changes that mediate beneficial effects of intravitreal bevacizumab in experimental 
branch retinal vein occlusion (BRVO).
Methods: In six Danish Landrace pigs, BRVO was induced with argon laser in both eyes. After BRVO was induced, the 
right eye of each animal was given an intravitreal injection of bevacizumab while the left eye was treated with saline 
water. The retinas were collected 15 days after BRVO, and differentially expressed proteins were analyzed with tandem 
mass tags–based mass spectrometry. Validation of statistically significantly changed proteins was performed with im-
munohistochemistry and western blotting.
Results: Fluorescein angiography showed no recanalization of the occluded vessels. A total of 4,013 proteins were 
successfully identified and quantified. Nine proteins were statistically significantly changed following bevacizumab 
intervention. In experimental BRVO, bevacizumab treatment resulted in upregulation of transthyretin (TTR) and pan-
tothenate kinase 3. Bevacizumab downregulated protocadherin 7, protein FAM192A, and ATP synthase protein 8. 
Immunohistochemistry revealed that TTR was highly abundant in the choroid following bevacizumab intervention.
Conclusions: Bevacizumab intervention in experimental BRVO resulted in an increased level of TTR. This is the 
second study in which we showed an increased retinal level of TTR following anti-vascular endothelial growth factor 
(VEGF) intervention in experimental BRVO. We hypothesize that there is an interaction between TTR and VEGF and 
that bevacizumab may exert a beneficial effect on the retina by upregulating TTR.
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a branch retinal vein in the inferior retina as described in 
previous works [4,5]. Briefly, BRVO was induced close to 
the optic head with a standard argon laser (532 nm) given by 
indirect ophthalmoscopy using a 20 D lens. The laser settings 
were 400 mW and 550 ms. A total of 30–40 laser applications 
were used per occlusion. BRVO was considered successful 
when flame-shaped hemorrhages appeared and stagnation of 
venous blood was observed.
Before the intravitreal injections, povidone iodine eye 
drops were applied in both eyes (Skanderborg Pharmacy, 
Skanderborg, Denmark). Approximately 15 min after 
successful BRVO was observed, the right eyes received 
an intravitreal injection of 0.05 ml bevacizumab 25 mg/ml 
(Avastin, Roche, Hvidovre, Denmark). The left eyes were 
given an intravitreal injection of 0.05 ml sodium chloride 
9 mg/ml (NaCl; B. Braun, Frederiksberg, Denmark). After 
the injections, chloramphenicol ointment 1% (Takeda 
Pharma A/S, Taastrup, Denmark) was applied in both eyes. 
Fluorescein angiography was performed 5 days after BRVO 
to confirm that the veins remained occluded. Fifteen days 
after BRVO, the eyes were enucleated, and the animals were 
euthanized immediately after enucleation. Euthanasia was 
performed with an intravenous injection of Euthasol (Virbac 
Danmark A/S, Kolding, Denmark) 400 mg/ml, 0.5 ml/kg.
Sample preparation for mass spectrometry: Right eyes (beva-
cizumab, n=5) and left eyes (NaCl, n=5) from five animals 
were used for mass spectrometry based on quantification with 
tandem mass tags (TMT). The neurosensory retinas were 
collected as previously described [4] and stored at −80 °C 
until further use. One hundred micrograms from each of 
the ten retinal samples were transferred to a new tube, and 
100 mM triethyl ammonium bicarbonate (TEAB) were added 
until a volume of 100 µl was reached. Reduction of disulfide 
bonds, alkylation, acetone precipitation, and digestion with 
trypsin were performed as described in recent works [4,5]. 
Labeling with TMT, C18 spin column purification, and high 
pH reversed-phase peptide fractionation into eight fractions 
were performed as described in a previous work [5].
Liquid chromatography mass spectrometry: The eight frac-
tions containing the peptides were resuspended in 0.1% formic 
acid (FA) before liquid chromatography mass spectrometry 
was performed. Six microliters of each sample were injected 
into a Dionex RSLC nanoUPLC system connected to an Orbi-
trap Fusion mass spectrometer (Thermo Scientific, Waltham, 
MA) equipped with an Easy Spray ion source. Liquid chro-
matography and mass spectrometry in TMT synchronous 
precursor selection MS3 mode were performed as described 
in a previous work [4]. With the Sequest HT database, mass 
spectrometry raw data were searched against the Uniprot 
Sus scrofa database and the Homo sapiens Uniprot database 
using Proteome Discoverer 2.1 as previously described [5]. A 
false discovery rate of 1% was used to identify proteins. The 
false discovery rate was calculated using the automated false 
discovery rate calculations of Proteome Discoverer that uses a 
Decoy Database search to determine the false discovery rate.
Statistical analysis: Mass spectrometry data were further 
processed with Perseus (version 1.6.0.0) that was used to 
remove poorly identified proteins as described in a previous 
Figure 1. Experimental overview. Branch retinal vein occlusion (BRVO) was induced in both eyes of six Danish Landrace pigs. After 
successful occlusion had been observed, the right eyes were given an intervention with bevacizumab while the left eyes received an injection 
containing saline water (NaCl). Fluorescein angiography was conducted 5 days after BRVO to confirm that the veins remained occluded. 
The eyes were enucleated and dissected 15 days after BRVO. Paired retinal samples from five animals were used for proteomic analysis with 
mass spectrometry followed by western blotting. Thus, samples with BRVO + bevacizumab (n=5) were compared to BRVO + NaCl (n=5). 
Eyes from one animal were used for validation with immunohistochemistry.
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article [4]. In Perseus, TMT abundances were log2 trans-
formed, and a valid value in each of the ten samples was 
required. At least two unique peptides were required. A paired 
t test conducted in Perseus was used for statistical analysis. 
Before fold changes were calculated, the log2 transformation 
was reversed. Fold changes were then calculated as the ratio 
of TMT abundance of the right eye to the TMT abundance 
of the left eye. Proteins were considered statistically signifi-
cantly changed if p<0.05 and fold change >1.25 or fold change 
<0.8. Regulated keratins were considered contaminants.
Western blotting: Western blotting was conducted as previ-
ously described [4]. Samples for mass spectrometry were also 
used for western blotting after TEAB buffer was added. For 
this study, a primary monoclonal mouse anti-β-actin antibody 
1:5,000 (clone AC-15, Sigma-Aldrich, Søborg, Denmark) and 
a primary polyclonal sheep anti-transthyretin (TTR) antibody 
1:5,000 (ab9015, Abcam, Cambridge, UK) were used. Both 
antibodies were diluted in 2.5% (w/v) skim milk blocking 
buffer. Horseradish peroxidase (HRP)–conjugated secondary 
antibodies polyclonal goat anti-mouse immunoglobulins/
HRP (Dako, Glostrup, Denmark) and rabbit anti-sheep IgG 
eavy and light chains (ab6747, Abcam, Cambridge, UK) were 
used, diluted 1;30,000 and 1:1;000, respectively, in 2.5% (w/v) 
skim milk blocking buffer.
Immunohistochemistry: Eyes from one animal were used for 
immunohistochemistry to compare BRVO + bevacizumab 
(n=1) to BRVO + NaCl (n=1). Immunohistochemical analyses 
were performed on retinal sections containing the occlusions. 
Fixation was performed using a fixative of 99% ethanol 
(three parts) and glacial acetic acid (one part) as previously 
described [4]. A polyclonal IgG antibody directed at TTR 
(ab9015, Abcam) was used for immunohistochemistry. Sheep 
antibodies were diluted (1:200 to 1:800) in PBS (1X; 137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 
pH 7.4) with 0.3% Triton X100. Retinal sections were incu-
bated overnight at 4 °C and were processed using EnVission 
(DakoCytomation, Glostrup, Denmark) DAB. Controls were 
incubated with either sheep IgG2b alone or irrelevant sheep 
antibodies.
RESULTS
Experimental branch retinal vein occlusion: Experimental 
BRVO was successfully induced in both eyes of each animal 
based on the development of venous dilation and the appear-
ance of flame-shaped hemorrhages (Figure 2). Fluorescein 
angiography 5 days after BRVO showed no recanalization of 
the occluded veins (Figure 3A,B).
Protein quantification with mass spectrometry: Results of 
the database search are provided in Appendix 1. A total of 
Figure 2. Fundus image of BRVO 
obtained approximately 10 min 
after BRVO in the inferior retina. 
Branch retinal vein occlusion 
(BRVO) was considered successful 
when venous dilation and hemor-
rhages were observed upstream 
of the site of occlusion as seen in 
the image. Black arrow: site of 
occlusion.
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4,013 proteins were successfully identified after filtering 
(Appendix 2). When no cut-offs were applied, 397 proteins 
were statistically significantly changed. When cut-offs were 
applied, a total of nine proteins were found to be statistically 
significantly changed following bevacizumab intervention 
(Table 1). Bevacizumab intervention resulted in upregulation 
of immunoglobulin kappa chain C region (fold change=12.50, 
p= 0.0039), immunoglobulin gamma-1 chain C region (fold 
change=11.55, p=0.0054), and immunoglobulin gamma-3 
chain C region (fold change=2.41, p=0.015). Bevacizumab 
intervention also resulted in upregulation of TTR (fold 
change=2.36, p=0.025) and pantothenate kinase 3 (fold 
change=1.31, p=0.014). A number of proteins were found to 
be statistically significantly downregulated. These proteins 
included isoform B of protocadherin 7 (fold change=0.79, 
p=0.0016), protein FAM192A (fold change=0.79, p=0.030), 
and ATP synthase protein 8 (fold change=0. 76, p=0.011).
Immunohistochemistry and western blotting: Immunohis-
tochemistry revealed that TTR was present in all retinal 
layers and that TTR was abundant in the retinal vasculature 
regardless of bevacizumab intervention (Figure 4). Staining 
for TTR was particularly pronounced in the choroid in BRVO 
Figure 3. Fluorescein angiography was obtained 5 days after BRVO to confirm that no recanalization of the occluded veins had occurred. 
Images from the same animal are shown. No passage of fluorescein through the sites of occlusion is observed. A: Fluorescein angiography 
of branch retinal vein occlusion (BRVO) with bevacizumab intervention. White arrow: site of occlusion. B: Fluorescein angiography of 
BRVO without bevacizumab intervention. White arrow: site of occlusion.
Table 1. SignificanTly changed proTeinS ordered according To fold change.
UniProt ID Protein name Gene name P-value Fold change
P01834 Immunoglobulin kappa chain C region IGKC 0.0039 12.50
P01857 Immunoglobulin gamma-1 chain C region IGHG1 0.0054 11.55
P01860 Immunoglobulin gamma-3 chain C region IGHG3 0.015 2.41
P50390 Transthyretin (TTR) TTR 0.025 2.36
P04264 Keratin, type II cytoskeletal 1 KRT1 0.018 1.90
Q9H999 Pantothenate kinase 3 PANK3 0.014 1.31
O60245–2 Isoform B of Protocadherin-7 PCDH7 0.0016 0.79
Q9GZU8 Protein FAM192A FAM192A 0.030 0.79
Q35914 ATP synthase protein 8 ATP8 0.011 0.76
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treated with bevacizumab (Figure 4A) while choroid staining 
for TTR was weaker in BRVO treated with NaCl (Figure 
4B). Western blotting confirmed the upregulation of TTR 
following bevacizumab intervention (p=0.045; Figure 5).
DISCUSSION
Experimental BRVO and bevacizumab intervention: Laser-
induced BRVO is a well-established model, and we have 
shown in previous studies that occluded vessels do not 
recanalize [4-7]. In the present study, BRVO was validated 
with fluorescein angiography 5 days after BRVO. As we 
have previously demonstrated that occlusion is sustained in 
the model [4,7], we are confident that the vessels remained 
occluded throughout the study.
In the present study, the bevacizumab intervention was 
given shortly after BRVO was induced. From previous studies 
[5,7], we learned that some recovery takes place in experi-
mental BRVO. Therefore, an intravitreal intervention should 
be given in the acute stage of BRVO [4]. Ideally, intravitreal 
bevacizumab should be injected 24 h after experimental 
BRVO, but some animals may suffer from fatigue if they 
are exposed to anesthesia on 2 consecutive days. To give the 
intervention in the acute stage of BRVO and to avoid fatigue 
in the animals, the anti-VEGF intervention was administered 
approximately 15 min after BRVO.
Focal adhesion and plasma proteins: We previously 
demonstrated that BRVO results in upregulation of proteins 
involved in focal adhesion, including laminins, integrin β-1, 
osteopontin, talin-2, actinins, filamin-C, and myosin 9 [7]. 
The present study demonstrated that BRVO is associated 
with multiple protein changes that are not reversed through 
neutralization of VEGF with bevacizumab. Resistance 
to anti-VEGF treatment is a common phenomenon in the 
treatment of retinal vein occlusion [8], and some patients 
are considered anti-VEGF non-responders [9]. The fact that 
BRVO causes a multitude of protein alterations may explain 
why some patients do not respond to anti-VEGF therapy. 
Multiple protein changes in BRVO may also explain why 
Figure 4. Immunohistochemical staining for TTR. Mass spectrometry revealed upregulation of transthyretin (TTR) which was further 
characterized with immunohistochemistry. Staining for TTR revealed that TTR was present in all retinal layers and in the choroid. A strong 
reaction for TTR was seen in the retinal vessels regardless of bevacizumab intervention. A: In branch retinal vein occlusion (BRVO) with 
bevacizumab intervention, a strong reaction for TTR was observed in the choroid. In the choroid, the reaction for TTR was stronger in BRVO 
with bevacizumab intervention (A) compared to BRVO without bevacizumab intervention (B). Therefore, the choroid may be the source 
of increased TTR in BRVO with bevacizumab intervention. Scale bar = 50 µm. Reaction color: brown. Abbreviations: ILM: inner limiting 
membrane; NFL: nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform 
layer; ONL: outer nuclear layer; PRL: photoreceptor layer. RPE: retinal pigment epithelium. CHO: choroid.
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visual function remains impaired despite successful treat-
ment of macular edema and neutralization of VEGF.
BRVO is known to cause disruption of the blood–retinal 
barrier followed by an influx of plasma proteins, such as 
fibrinogen chains, α-2-macroglobulin, and β-2-glycoprotein 
1 [7]. Anti-VEGF treatments are known to reestablish the 
blood–retinal barrier and to diminish leakage of fluid and 
plasma proteins [3]. Therefore, a lower plasma protein content 
was likely to be observed in BRVO with bevacizumab inter-
vention. However, there was no statistically significant differ-
ence in plasma proteins between BRVO with bevacizumab 
intervention and BRVO without bevacizumab intervention.
Transthyretin: Transthyretin is a tetramer consisting of 
four identical subunits. In the eye, TTR is synthesized by 
RPE cells but is known to have a wide distribution within 
the retinal layers [10,11]. TTR is a carrier of retinol binding 
protein and a minor carrier of thyroxine (T4) [12]. Immu-
nohistochemistry revealed a reaction for TTR in all retinal 
layers, but a pronounced reaction for TTR was identified 
in the choroid following bevacizumab treatment. Thus, the 
choroid may be the source of the increased content of TTR 
measured in BRVO treated with bevacizumab.
We previously tested the anti-VEGF agent ranibizumab 
on the BRVO model. Interestingly, neutralization of VEGF-A 
with ranibizumab also resulted in an increased level of TTR 
[5]. Thus, this is the second study in which we showed that 
anti-VEGF treatment increases retinal TTR in the BRVO 
model. Therefore, we find it highly unlikely that the increased 
level of TTR could be a result of multiple hypothesis testing. 
Although the data indicate that anti-VEGF agents increase 
the retinal content of TTR, the opposite scenario takes place 
in patients with mutations in the TTR gene who have been 
reported to have high levels of VEGF in the vitreous body. 
O’Hearn and coworkers [13] reported on a patient with an 
isolated Glu54Gly TTR mutation causing familial amyloi-
dotic polyneuropathy. This patient had an elevated level of 
vitreous VEGF of 854 pg/ml while the VEGF level was 128 
pg/ml in the vitreous from a control patient who underwent 
vitrectomy due to a macular hole. Zou et al. [14] reported 
on patients with the TTR Ala36Pro mutation which causes 
familial TTR amyloidosis. The vitreous VEGF concentration 
from patients with the TTR Ala36Pro mutation was found 
to be approximately threefold higher than in control patients 
with macular epiretinal membrane or macular hole. Further-
more, patients with the TTR Ala36Pro mutation had higher 
serum VEGF levels than healthy controls. Thus, case reports 
and our studies of the BRVO model suggest an interaction 
between TTR and VEGF, and we hypothesize that anti-VEGF 
agents exert a beneficial effect on the retina by upregulating 
TTR.
Figure 5. Western blot analysis of TTR. Western blotting confirmed that transthyretin (TTR) was statistically significantly increased in 
branch retinal vein occlusion (BRVO) treated with bevacizumab (p=0.045). A: Retinal content of TTR. B: Densitometric change of relative 
TTR content between BRVO + NaCl and BRVO with bevacizumab intervention normalized to relative β-actin expression. *p<0.05.
Molecular Vision 2018; 24:759-766 <http://www.molvis.org/molvis/v24/759> © 2018 Molecular Vision 
765
Mutations in the TTR gene are known to cause familial 
amyloidosis which often leads to ocular manifestations [15]. 
Patients with ocular manifestations generally have vitreous 
involvement with vitreous opacities [13-15]. Some patients 
with familial amyloidosis due to TTR mutations also present 
with tortuous retinal vessels, retinal hemorrhages, and 
neovascularization [13,15]. Veronese and coworkers [16] 
investigated the ocular manifestations of a patient with a 
rare amyloidogenic TTR Glu54Lys mutation. This patient 
was found to have sheathing of retinal vessels and retinal 
hemorrhages while fluorescein angiography showed micro-
aneurysms and perivascular focal staining. Therefore, it may 
be considered whether TTR prevents development of neovas-
cularizations and vascular leakage.
Immunoglobulin heavy chains: Bevacizumab intervention 
resulted in upregulation of three constant regions of immu-
noglobulin heavy chains. These chains included immuno-
globulin kappa chain C region, immunoglobulin gamma-1 
chain C region, and immunoglobulin gamma-3 chain C 
region. These immunoglobulin chains are likely to be compo-
nents of bevacizumab. In experimental BRVO treated with 
the anti-VEGF agent ranibizumab, we previously identified 
increased levels of immunoglobulin kappa chain C region and 
immunoglobulin gamma-1 chain C region which are thought 
to be components of ranibizumab [5].
Pantothenate kinase 3: Pantothenate kinase 3 (PanK3) is 
one of the four mammalian pantothenate kinase isoforms 
that control the rate of coenzyme A (CoA) biosynthesis [17]. 
PanK3 catalyzes the first step of CoA biosynthesis. CoA 
is a cofactor in several reactions, such as oxidation of fatty 
acids, carbohydrates, and amino acids [18]. To the best of 
our knowledge, the role of retinal PanK3 remains largely 
unstudied.
Protocadherin 7: Protocadherin 7 is an integral membrane 
protein. Protocadherins play a key role in neuronal develop-
ment [19]. Protocadherin 7 is known to be involved in cell 
proliferation, migration, and invasion [20]. Protocadherins 
are the largest cadherin subfamily [19]. The retinal distribu-
tion of protocadherin has been studied in ferret retinas as 
reported by Etzrodt and coworkers [19]. Protocadherin 7 is 
expressed in the nerve fiber layer, the ganglion cell layer, and 
the inner nuclear layer but is absent in the outer nuclear layer. 
The biological function of retinal protocadherin 7 remains 
largely unstudied.
Anti-VEGF versus dexamethasone: In the present study, we 
identified a total of nine proteins that were differentially 
regulated following bevacizumab intervention. This finding 
confirms that bevacizumab has a narrow mechanism of 
action in comparison to a dexamethasone (DEX) intravitreal 
implant (OZURDEX, Allergan) that is an alternative to beva-
cizumab. We previously tested a DEX intravitreal implant on 
the experimental BRVO model [4]. Using the same criteria as 
in the present study, we identified 26 proteins that were statis-
tically significantly changed following DEX intervention. 
Neutralization of VEGF-A with bevacizumab did not cause 
any changes in VEGF receptor-2 (VEGFR-2) in the BRVO 
model. In this aspect, bevacizumab differs from a DEX 
implant that causes a small downregulation of VEGFR-2 in 
experimental BRVO [4].
Conclusions: In experimental BRVO, bevacizumab increased 
the retinal level of TTR. Immunohistochemistry revealed 
pronounced staining for TTR in the choroid indicating that 
the choroid may be the source of TTR following bevacizumab 
intervention. This is the second study we have conducted 
that revealed an upregulation of TTR following anti-VEGF 
intervention in the BRVO model. We hypothesize that there 
is an interaction between TTR and VEGF and that anti-VEGF 
agents exert a beneficial effect on the retina by upregulating 
TTR. The proteomic analysis revealed that bevacizumab 
regulated only a limited number of retinal proteins and has a 
narrow mechanism of action compared to DEX intravitreal 
implants.
APPENDIX 1.
To access the data, click or select the words “Appendix 1.”
APPENDIX 2.
To access the data, click or select the words “Appendix 2.”
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